Bioconjugation Market Report 2026

The bioconjugation market size has grown rapidly in recent years. It will grow from $6.12 billion in 2025 to $6.89 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing biologics research activity, expansion of antibody-based therapeutics, growth of diagnostic assay development, rising adoption of protein labeling techniques, availability of standardized conjugation kits.

The bioconjugation market size is expected to see rapid growth in the next few years. It will grow to $11.12 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to increasing development of targeted drug conjugates, rising investments in precision medicine research, expansion of companion diagnostics, growing use of conjugated biomolecules in imaging, increasing demand for scalable conjugation workflows. Major trends in the forecast period include increasing adoption of site-specific conjugation techniques, rising use of advanced linker chemistries, growing demand for high-purity conjugation reagents, expansion of automated conjugation platforms, enhanced focus on stability and reproducibility.

The growing demand for targeted therapeutics is expected to drive the development of the bioconjugation market in the future. Targeted therapeutics are medical treatments designed to specifically address disease-causing cells or molecules, enhancing treatment efficacy while minimizing damage to healthy tissues. The rise in targeted therapeutics is fueled by increasing demand for precision medicine, which enables more accurate treatment strategies that improve patient outcomes and reduce adverse effects. Bioconjugation supports targeted therapeutics by precisely linking drugs to targeting molecules, improving selective delivery to diseased cells, and enhancing therapeutic performance. For instance, in February 2024, according to West China Hospital, Sichuan University, a China-based medical research center advancing targeted therapies, over 47 new targeted therapeutics were approved by the U.S. Food and Drug Administration in 2023, representing about 85.5% of all new drug approvals and indicating an increasing focus on precision-targeted treatment options in the United States. Therefore, the growing demand for targeted therapeutics is driving the growth of the bioconjugation market.

Key companies operating in the bioconjugation market are focusing on developing advanced platforms, such as site-specific conjugation methods, to improve drug delivery precision, enhance coupling stability, and minimize off-target toxicity. Site-specific conjugation methods refer to bioconjugation techniques that allow controlled attachment of therapeutic molecules, such as drugs or RNAi, to biomolecules like antibodies, peptides, or oligonucleotides, ensuring consistent activity and safety. For example, in August 2023, BOCSCI Inc., a US-based supplier of research chemicals and bioconjugation services, launched the XDC bioconjugation platform, a next-generation solution designed to optimize the synthesis of bioconjugates. Leveraging advanced conjugation strategies, including unnatural amino acid incorporation, engineered cysteine conjugation, enzyme-assisted ligation, and glycoconjugation generation, the platform enables precise manufacturing of antibody-drug conjugates, siRNA conjugates, and other targeted drug delivery molecules, empowering researchers to design safer and more effective biopharmaceuticals.

In July 2023, Biosynth Carbosynth, a Switzerland-based company providing custom synthesis and manufacturing services, acquired Celares for an undisclosed amount. Through this acquisition, Biosynth aims to expand its bioconjugation capabilities and polymer-based drug delivery solutions, enabling tailored conjugation of antibodies, antigens, and peptides for pharmaceutical and diagnostic customers from development through commercialization. Celera Corporation is a US-based company specializing in bioconjugation, polymer-based drug delivery, and the chemical modification of biomolecules to enhance therapeutic efficacy.

Major companies operating in the bioconjugation market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza Group AG, Agilent Technologies Inc., Charles River Laboratories International Inc., Sartorius AG, Bio-Rad Laboratories Inc., Vector Laboratories Inc., Promega Corporation, LGC Biosearch Technologies Ltd., TriLink BioTechnologies LLC, Creative PEGWorks Inc., Lumiprobe Corporation, Biotium Inc., Jena Bioscience GmbH, Quanta BioDesign Ltd., Setareh Biotech Inc., Baseclick GmbH, Biosynth Carbosynth Ltd., Glen Research Inc., BroadPharm Inc., and Biorbyt Ltd.

Tariffs are influencing the bioconjugation market by increasing costs of imported specialty reagents, linkers, enzymes, chromatography materials, and laboratory instrumentation used in conjugation workflows. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported consumables, while Asia-Pacific faces higher production costs for export-oriented research supplies. These tariffs are raising operational expenses and extending procurement timelines. However, they are also promoting regional reagent manufacturing, local supplier development, and increased investment in domestic life science supply chains.

The bioconjugation market research report is one of a series of new reports that provides bioconjugation market statistics, including bioconjugation industry global market size, regional shares, competitors with a bioconjugation market share, detailed bioconjugation market segments, market trends and opportunities, and any further data you may need to thrive in the bioconjugation industry. This bioconjugation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioconjugation is the chemical process of linking biomolecules such as proteins, peptides, nucleic acids, or carbohydrates to other molecules or functional surfaces. It allows controlled binding of biological components to labels, therapeutics, carriers, or materials while maintaining their biological function and specificity. The process combines selective chemistries, linker strategies, and stabilization techniques to ensure durable attachment, functional consistency, and compatibility with downstream biological and analytical applications.

The primary product types of bioconjugation include consumables, instruments, and service. Consumables consist of the reagents, kits, and materials required for conducting bioconjugation experiments. Bioconjugation is applied to multiple biomolecule types, including antibodies, proteins, peptides, oligonucleotides, and other biomolecules. It employs techniques such as chemical conjugation, enzyme-mediated conjugation, click chemistry, photoreactive crosslinking, and other techniques. These solutions support applications such as therapeutics, research and development, and diagnostics, and are utilized by end users including pharmaceutical and biotechnology companies, contract research organizations and contract manufacturing organizations, academic and research institutes, and hospitals, clinical, and diagnostic laboratories.

The bioconjugation market includes sales of linkers, crosslinkers, labeling reagents, and assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.